Abstract
Plasma concentrations of soluble urokinase plasminogen activator receptor (suPAR) predict mortality in several clinical settings, but the long-term prognostic importance of suPAR in chest pain patients admitted on suspicion of non-ST-segment elevation acute coronary syndrome (NSTEACS) is uncertain.
Originalsprog | Engelsk |
---|---|
Tidsskrift | Clinical Chemistry (Washington, DC) |
Vol/bind | 59 |
Udgave nummer | 11 |
Sider (fra-til) | 1621-1629 |
Antal sider | 9 |
ISSN | 0009-9147 |
DOI | |
Status | Udgivet - nov. 2013 |